Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
No, but. Cancer during pregnancy is not an uncommon thing but cancer itself rarely affects the growing baby directly. The cancers that tend to occur during pregnancy are also more common in younger people. These cancers include - Cervical Cancer, Breast Cancer, Thyroid Cancer, Melanoma, Gestat....
Generally, women having their routine mammogram will receive a letter within one month with normal results. But if the doctor finds something suspicious, they’ll call you back, mostly within just 5 days, to take fresh pictures or other tests. Yes, that call may seem to be scary, but a suspicious fin....
Yes...There are many stories with happy ending. Chemo is not the end of your life. Every day is a gift... that's what chemo reminds you. The majority of women who develop breast cancer around the world will not die of breast cancer. In fact, 8 out of 10 women who are diagnosed with breast cancer wil....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
लेखक:Dr. Nitika Sharma - BDS
समीक्षा की गई:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.